NCI Director Named as Acting FDA Commissioner
Ned Sharpless is tapped to take on acting commissioner role following Gottlieb’s resignation.
One week following the surprise resignation of FDA Commissioner Scott Gottlieb, Norman E. (Ned) Sharpless, head of the National Cancer Institute (NCI), was named acting commissioner of FDA, according to media reports.
The announcement was confirmed by Health and Human Services Secretary Alex Azar at a congressional hearing on March 12, 2019.
Sharpless has served as the director of NCI since October 2017. He previously was director of the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center, served on the faculty at Harvard Medical School, and the University of North Carolina School of Medicine in the Departments of Medicine and Genetics.
He cofounded clinical-stage biotechnology companies G1 Therapeutics and HealthSpan Diagnostics, according to his NCI biography.
Source: NCI
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
